To be fair, the product does sit in a slight grey zone, where it is competing against drugs and isn't an inert medical device such as a stent, for instance. That said, Bell Potter have a long history of being wrong.
However, colleagues who have been involved in the trial of this product have been genuinely impressed by its effect in down staging borderline resectable pancreatic cancer in some patients. Given the lack of effective chemotherapy options, this probably does have a place in pancreatic cancer treatment, and given that this is a rapidly increasing tumour it would appear that this product is going to get used.
- Forums
- ASX - By Stock
- OSL Top Pick for FY21
To be fair, the product does sit in a slight grey zone, where it...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
|
|||||
Last
1.2¢ |
Change
0.002(20.0%) |
Mkt cap ! $45.40M |
Open | High | Low | Value | Volume |
1.1¢ | 1.2¢ | 1.1¢ | $137.7K | 12.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 3725013 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 3489246 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 3275013 | 0.011 |
13 | 10106250 | 0.010 |
22 | 15548486 | 0.009 |
5 | 5537600 | 0.008 |
15 | 5041678 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 3489246 | 5 |
0.013 | 11116832 | 6 |
0.014 | 8965166 | 13 |
0.015 | 8916666 | 4 |
0.016 | 3770668 | 3 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online